
Dexcom
DXCM · NASDAQ · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $31,1 bn
- Div. yield
- —
- Year to date
- +25,6%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
8 ✓ · 0 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 31,4 | 76,4 | 25,1 |
| Forward P/E | 26,8 | — | 16,2 |
| PEG | 1,4 | — | 2,2 |
| P/S | 6,1 | 10,8 | 2,2 |
| EV/EBITDA | 21,0 | 66,9 | 17,3 |
| P/FCF | 28,3 | — | 19,5 |
| P/B | 12,3 | 15,3 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 36 analysts
- Buy
- 32
- Hold
- 4
- Sell
- 0
Beat the EPS forecast in 3 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 0,69 | 0,73 | Up +6,2% |
| Q2 2026 | 0,62 | 0,70 | Up +12,4% |
| Q1 2026 | 0,48 | 0,56 | Up +17,0% |
| Q4 2025 | 0,66 | 0,45 | Down −32,1% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,34 bn | 1,31 bn | 1,19 bn | 1,26 bn | 1,21 bn | 1,16 bn | 1,04 bn | 1,11 bn | 994 m | 1,00 bn | 921 m | 1,03 bn |
| EPS | 0,72 | 0,64 | 0,51 | 0,67 | 0,70 | 0,45 | 0,27 | 0,38 | 0,34 | 0,35 | 0,36 | 0,61 |
| Margin | 20,5% | 19,0% | 16,7% | 21,2% | 23,5% | 15,5% | 10,2% | 13,6% | 13,5% | 14,3% | 15,9% | 24,8% |
| FCF | 273 m | 185 m | 449 m | 192 m | 579 m | 209 m | 96,8 m | 177 m | 88,3 m | 213 m | 152 m | 81,1 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $12,2 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| stern sadie27 Oct 2026 · sale | $201 660 | 2 565 | $78,62 |
| augustinos nicholas15 Sep 2026 · sale | $549 538 | 6 539 | $84,04 |
| brown michael jon15 Sep 2026 · sale | $142 868 | 1 700 | $84,04 |
| augustinos nicholas14 Sep 2026 · sale | $130 231 | 1 550 | $84,02 |
| sylvain jereme m10 Sep 2026 · sale | $302 936 | 3 638 | $83,27 |
| stern sadie27 Aug 2026 · sale | $226 669 | 2 565 | $88,37 |
| sayer kevin r20 Aug 2026 · sale | $8 867 | 97 | $91,41 |
| sayer kevin r20 Aug 2026 · sale | $667 332 | 7 351 | $90,78 |
| sayer kevin r20 Aug 2026 · sale | $1,73 m | 19 308 | $89,71 |
| brown michael jon14 Aug 2026 · sale | $156 281 | 1 700 | $91,93 |
| heller bridgette p12 Aug 2026 · sale | $89 349 | 1 012 | $88,29 |
| foletta mark g3 Aug 2026 · sale | $170 640 | 2 000 | $85,32 |
| foletta mark g31 Jul 2026 · sale | $160 000 | 2 000 | $80,00 |
| sayer kevin r20 Jul 2026 · sale | $2,04 m | 26 756 | $76,32 |
| brown michael jon15 Jul 2026 · sale | $126 514 | 1 700 | $74,42 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NASDAQ
- Country
- US
- IPO date
- 14 Apr 2005
- Website
- www.dexcom.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
LHLabcorp | $372,46 | 56★★★★★★★★would watch | 30,0 | +6,0% | 6,9% |
DGXQuest Diagnostics | $262,21 | 61★★★★★★★★would watch | 25,5 | +9,1% | 9,5% |
RMDResMed | $238,19 | 83★★★★★★★★★would consider | 21,3 | +9,0% | 27,8% |
CNCCentene Corporation | $74,77 | 72★★★★★★★★★would consider | 24,2 | +9,7% | 0,7% |
GEHCGE HealthCare | $82,96 | no score | 17,4 | — | — |
Ratio — a score by our methodology, not an investment recommendation.




